Jessica Hergert

Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com

Articles

Efficacy of Cevostamab Increases With Higher Doses in Heavily Pretreated Multiple Myeloma

December 14th 2021

Cycle 1 double step-up dosing with cevostamab demonstrated encouraging activity with effective cytokine release syndrome mitigation in patients with heavily pretreated relapsed/refractory multiple myeloma, supporting further development of the dual-targeted bispecific antibody.

Tisagenlecleucel Fails to Improve EFS in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

December 14th 2021

As second-line treatment, tisagenlecleucel failed to demonstrate an event-free survival advantage compared with standard of care platinum-based chemotherapy followed by autologous stem cell transplant or additional chemotherapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Tisagenlecleucel Continues to Show Favorable Real-World Efficacy and Safety in R/R B-Cell Non-Hodgkin Lymphomas

December 12th 2021

Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Frontline Venetoclax-Based Combos Improve uMRD Rates Vs Chemoimmunotherapy in Fit Patients With CLL

December 11th 2021

The combination of obinutuzumab and venetoclax (GVe), as well as GVe plus ibrutinib demonstrated superior rates of undetectable minimal residual disease compared with chemoimmunotherapy in fit patients with chronic lymphocytic leukemia, according to findings from the phase 3 GAIA (CLL13) trial.

Fulvestrant/Palbociclib Following AI/Palbociclib Doubles PFS in HR+/HER2- Metastatic Breast Cancer

December 7th 2021

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer with rising ESR1 mutations previously treated with an aromatase inhibitor plus palbociclib had a doubling of progression-free survival when switched to fulvestrant plus palbociclib before disease progression, according to findings from the phase 3 PADA-1 trial.

Frontline Pembrolizumab Plus Chemotherapy Approved in Japan for Esophageal Carcinoma

November 30th 2021

The Japan Pharmaceuticals and Medical Devices Agency has approved the PD-1 inhibitor pembrolizumab for frontline use in combination with 5-fluorouracil plus cisplatin chemotherapy in patients with radically unresectable, advanced, or recurrent esophageal carcinoma.

Abiraterone/Docetaxel Combo Associated With Improved QOL Vs Docetaxel in mHSPC

November 30th 2021

Patients with locally advanced or metastatic hormone-sensitive prostate cancer who received docetaxel and abiraterone acetate plus prednisone or prednisolone and standard of care androgen deprivation therapy had superior patient-reported quality of life compared with patients who received docetaxel plus ADT, although the improvement narrowly missed the predefined value for clinical significance.

Novel Therapies Propel the Paradigms of Breast and Gynecologic Cancers Forward

November 28th 2021

Panelists discuss the latest advances in targeting HER2-positive breast cancer, the rapidly evolving landscape of triple-negative breast cancer, the role of maintenance therapy in ovarian cancer, and recent updates in the treatment of patients with endometrial and cervical cancers.

New ASTRO President Calls Attention to In-Person Meetings, Remaining Challenges, and Ongoing Research in Radiation Oncology

November 24th 2021

Jeff M. Michalski, MD, MBA, FASTRO, shares his presidential goals for ASTRO, the success of the hybrid 2021 ASTRO Annual Meeting, and remaining questions in radiation oncology that research efforts are poised to address.

Advances in Diagnostics and Therapeutics Propel Interventional Pulmonology Forward

November 23rd 2021

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.

Advances With Systemic Therapy and Surgery Underscore the Need for Multidisciplinary Care in Ovarian Cancer

November 22nd 2021

Utilizing a multidisciplinary approach to care is critical in the field of ovarian cancer with the substantial advancements that have been made with systemic chemotherapeutic regimens, PARP inhibitors, maintenance therapy, and surgical interventions.

Variable Chronic GVHD Presentations Stress the Need for Close Symptom Monitoring

November 22nd 2021

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses the variability in cGVHD presentation, key symptoms of the disease in patients with cancer, and how the field is navigating between available therapies.

Progress Made Across Breast Cancer Paradigm Sets the Stage for Improved Sequencing and Future Research

November 18th 2021

Sarah Sammons, MD, discusses key advances made across the spectrum of breast cancer, including HER2-positive, hormone receptor–positive, and triple-negative disease, as well as key data that have reshaped these paradigms.

Compressive Osseointegrated Endoprostheses Provide Long-Term Benefit in Bone Sarcoma

November 18th 2021

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

Experts Chip Away at Resistance, Sequencing, and Targeted Therapy Selection in Lung Cancer

November 17th 2021

Edgardo Santos, MD, discusses the current state of targeted therapies for EGFR- and ALK-positive non–small cell lung cancer, as well as immunotherapy in stage III NSCLC, and management strategies in small cell lung cancer.

Surufatinib/Toripalimab Combo Elicits Encouraging Efficacy in Advanced Neuroendocrine Carcinoma

November 13th 2021

The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.

PD-L1/4-1BB–Directed Bispecific Antibody ATG-101 Shows Preclinical Efficacy Without Hepatotoxicity

November 12th 2021

ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.

Investigators Set Their Sights on Optimizing Sequencing With Novel Therapies in GU Cancers

November 12th 2021

Treatment selection and sequencing in genitourinary cancers, such as metastatic bladder cancer and metastatic renal cell carcinoma, have become more complicated and require nuanced decision making.

Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL

November 5th 2021

Significant progress with rapidly evolving therapies, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, has been made to extend the median overall survival and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC

November 5th 2021

Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.